Sysmex Corporation Revises Earnings Forecast Upward on Strong US Demand
Sysmex Corporation (TSE:6869) raised its earnings guidance for the fiscal year ending March 2027, citing robust hematology equipment sales in the Americas and favorable currency movements.
| Item | Before | After | Change |
|---|---|---|---|
| Revenue | JPY 255.0bn | JPY 265.0bn | +3.9% |
| Operating Profit | JPY 23.0bn | JPY 25.0bn | +8.7% |
| 税引前利益 | JPY 21.0bn | JPY 23.0bn | +9.5% |
| 親会社の所有者に帰属する中間利益 | JPY 14.0bn | JPY 15.0bn | +7.1% |
| 基本的１株当たり中間利益 | JPY 22.53/share | JPY 24.68/share | +JPY 2.15/share |
For the six-month interim period ending September 30, 2026, the diagnostic equipment manufacturer raised revenue guidance by JPY 10.0bn to JPY 265.0bn, with operating profit lifted JPY 2.0bn to JPY 25.0bn. Full-year revenue is now projected at JPY 545.0bn, up JPY 10.0bn, while operating profit is forecast at JPY 60.0bn, a JPY 2.0bn increase. Pre-tax profit guidance rose JPY 2.0bn to JPY 23.0bn for the interim period and JPY 2.0bn to JPY 56.0bn for the full year.
The revision reflects stronger-than-anticipated performance in the Americas hematology segment during the first quarter, combined with yen weakness versus the dollar that exceeded initial assumptions. The currency tailwind provides additional upside to reported earnings when converting overseas revenue to yen.
The upward revision signals sustained momentum in Sysmex’s core diagnostic business, particularly in North America, a key growth market. The currency benefit, while cyclical, provides near-term earnings support. Investors should monitor whether the Americas hematology strength persists and track yen movements, as further appreciation could pressure full-year results.
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Always verify against the original filing.